The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics
CYP2D6 and CYP2C19 enzymes are essential in the metabolism of antidepressants and antipsychotics. Genetic variation in these genes may increase risk of adverse drug reactions. Antidepressants and antipsychotics have previously been associated with risk of diabetes. We examined whether individual gen...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ed317ea14eac4e45bfe9e12655c30a90 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ed317ea14eac4e45bfe9e12655c30a90 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ed317ea14eac4e45bfe9e12655c30a902021-11-25T17:41:35ZThe Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics10.3390/genes121117582073-4425https://doaj.org/article/ed317ea14eac4e45bfe9e12655c30a902021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4425/12/11/1758https://doaj.org/toc/2073-4425CYP2D6 and CYP2C19 enzymes are essential in the metabolism of antidepressants and antipsychotics. Genetic variation in these genes may increase risk of adverse drug reactions. Antidepressants and antipsychotics have previously been associated with risk of diabetes. We examined whether individual genetic differences in <i>CYP2D6</i> and <i>CYP2C19</i> contribute to these effects. We identified 31,579 individuals taking antidepressants and 2699 taking antipsychotics within UK Biobank. Participants were classified as poor, intermediate, or normal metabolizers of CYP2D6, and as poor, intermediate, normal, rapid, or ultra-rapid metabolizers of CYP2C19. Risk of diabetes mellitus represented by HbA1c level was examined in relation to the metabolic phenotypes. CYP2D6 poor metabolizers taking paroxetine had higher Hb1Ac than normal metabolizers (mean difference: 2.29 mmol/mol; <i>p</i> < 0.001). Among participants with diabetes who were taking venlafaxine, CYP2D6 poor metabolizers had higher HbA1c levels compared to normal metabolizers (mean differences: 10.15 mmol/mol; <i>p</i> < 0.001. Among participants with diabetes who were taking fluoxetine, CYP2D6 intermediate metabolizers and decreased HbA1c, compared to normal metabolizers (mean difference −7.74 mmol/mol; <i>p</i> = 0.017). We did not observe any relationship between CYP2D6 or CYP2C19 metabolic status and HbA1c levels in participants taking antipsychotic medication. Our results indicate that the impact of genetic variation in CYP2D6 differs depending on diabetes status. Although our findings support existing clinical guidelines, further research is essential to inform pharmacogenetic testing for people taking antidepressants and antipsychotics.Isabelle Austin-ZimmermanMarta WronskaBaihan WangHaritz IrizarJohan H. ThygesenAnjali BhatSpiros DenaxasGhazaleh FatemifarChris FinanJasmine Harju-SeppänenOlga GiannakopoulouKaroline KuchenbaeckerEirini ZartaloudiAndrew McQuillinElvira BramonMDPI AGarticleCYP2C19CYP2D6pharmacogeneticsdiabetespersonalized medicineHbA1cGeneticsQH426-470ENGenes, Vol 12, Iss 1758, p 1758 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
CYP2C19 CYP2D6 pharmacogenetics diabetes personalized medicine HbA1c Genetics QH426-470 |
| spellingShingle |
CYP2C19 CYP2D6 pharmacogenetics diabetes personalized medicine HbA1c Genetics QH426-470 Isabelle Austin-Zimmerman Marta Wronska Baihan Wang Haritz Irizar Johan H. Thygesen Anjali Bhat Spiros Denaxas Ghazaleh Fatemifar Chris Finan Jasmine Harju-Seppänen Olga Giannakopoulou Karoline Kuchenbaecker Eirini Zartaloudi Andrew McQuillin Elvira Bramon The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| description |
CYP2D6 and CYP2C19 enzymes are essential in the metabolism of antidepressants and antipsychotics. Genetic variation in these genes may increase risk of adverse drug reactions. Antidepressants and antipsychotics have previously been associated with risk of diabetes. We examined whether individual genetic differences in <i>CYP2D6</i> and <i>CYP2C19</i> contribute to these effects. We identified 31,579 individuals taking antidepressants and 2699 taking antipsychotics within UK Biobank. Participants were classified as poor, intermediate, or normal metabolizers of CYP2D6, and as poor, intermediate, normal, rapid, or ultra-rapid metabolizers of CYP2C19. Risk of diabetes mellitus represented by HbA1c level was examined in relation to the metabolic phenotypes. CYP2D6 poor metabolizers taking paroxetine had higher Hb1Ac than normal metabolizers (mean difference: 2.29 mmol/mol; <i>p</i> < 0.001). Among participants with diabetes who were taking venlafaxine, CYP2D6 poor metabolizers had higher HbA1c levels compared to normal metabolizers (mean differences: 10.15 mmol/mol; <i>p</i> < 0.001. Among participants with diabetes who were taking fluoxetine, CYP2D6 intermediate metabolizers and decreased HbA1c, compared to normal metabolizers (mean difference −7.74 mmol/mol; <i>p</i> = 0.017). We did not observe any relationship between CYP2D6 or CYP2C19 metabolic status and HbA1c levels in participants taking antipsychotic medication. Our results indicate that the impact of genetic variation in CYP2D6 differs depending on diabetes status. Although our findings support existing clinical guidelines, further research is essential to inform pharmacogenetic testing for people taking antidepressants and antipsychotics. |
| format |
article |
| author |
Isabelle Austin-Zimmerman Marta Wronska Baihan Wang Haritz Irizar Johan H. Thygesen Anjali Bhat Spiros Denaxas Ghazaleh Fatemifar Chris Finan Jasmine Harju-Seppänen Olga Giannakopoulou Karoline Kuchenbaecker Eirini Zartaloudi Andrew McQuillin Elvira Bramon |
| author_facet |
Isabelle Austin-Zimmerman Marta Wronska Baihan Wang Haritz Irizar Johan H. Thygesen Anjali Bhat Spiros Denaxas Ghazaleh Fatemifar Chris Finan Jasmine Harju-Seppänen Olga Giannakopoulou Karoline Kuchenbaecker Eirini Zartaloudi Andrew McQuillin Elvira Bramon |
| author_sort |
Isabelle Austin-Zimmerman |
| title |
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| title_short |
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| title_full |
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| title_fullStr |
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| title_full_unstemmed |
The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics |
| title_sort |
influence of cyp2d6 and cyp2c19 genetic variation on diabetes mellitus risk in people taking antidepressants and antipsychotics |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/ed317ea14eac4e45bfe9e12655c30a90 |
| work_keys_str_mv |
AT isabelleaustinzimmerman theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT martawronska theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT baihanwang theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT haritzirizar theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT johanhthygesen theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT anjalibhat theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT spirosdenaxas theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT ghazalehfatemifar theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT chrisfinan theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT jasmineharjuseppanen theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT olgagiannakopoulou theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT karolinekuchenbaecker theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT eirinizartaloudi theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT andrewmcquillin theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT elvirabramon theinfluenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT isabelleaustinzimmerman influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT martawronska influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT baihanwang influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT haritzirizar influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT johanhthygesen influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT anjalibhat influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT spirosdenaxas influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT ghazalehfatemifar influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT chrisfinan influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT jasmineharjuseppanen influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT olgagiannakopoulou influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT karolinekuchenbaecker influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT eirinizartaloudi influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT andrewmcquillin influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics AT elvirabramon influenceofcyp2d6andcyp2c19geneticvariationondiabetesmellitusriskinpeopletakingantidepressantsandantipsychotics |
| _version_ |
1718412139014651904 |